Leptin induces leiomyoma cell proliferation and extracellular matrix deposition via JAK2/STAT3 and MAPK/ERK pathways

Lauren Reschke M.D., Sadia Afrin Ph.D., Malak El Sabah M.D., Natasha Charewycz B.S., Mariko Miyashita-Ishiwata M.D., Ph.D., Mostafa A. Borahay M.D., Ph.D., M.B.A.
{"title":"Leptin induces leiomyoma cell proliferation and extracellular matrix deposition via JAK2/STAT3 and MAPK/ERK pathways","authors":"Lauren Reschke M.D.,&nbsp;Sadia Afrin Ph.D.,&nbsp;Malak El Sabah M.D.,&nbsp;Natasha Charewycz B.S.,&nbsp;Mariko Miyashita-Ishiwata M.D., Ph.D.,&nbsp;Mostafa A. Borahay M.D., Ph.D., M.B.A.","doi":"10.1016/j.xfss.2022.05.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the molecular effects of leptin on uterine leiomyoma cells.</p></div><div><h3>Design</h3><p>Experimental study using in vitro culture of immortalized human leiomyoma (HuLM) cells.</p></div><div><h3>Setting</h3><p>Academic university center.</p></div><div><h3>Patient(s)</h3><p><span>Women with uterine fibroids who underwent a hysterectomy or </span>myomectomy.</p></div><div><h3>Intervention(s)</h3><p>Administration of human recombinant leptin<span> to the media of cultured HuLM cells separately or in combination with pharmacologic Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) or mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) inhibitors.</span></p></div><div><h3>Main Outcome Measure(s)</h3><p><span>We examined HuLM tissues and cells for the expression of the leptin receptor<span>, termed OB-R. Cellular proliferation was measured at 6, 24, and 48 hours using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2</span></span><em>H</em><span><span><span>-tetrazolium bromide assay. Protein expression<span> levels of proliferating cell nuclear antigen, </span></span>collagen 1, phosphorylated STAT3/total STAT3, and phosphorylated ERK1/2 and total ERK1/2 were quantified using </span>immunoblotting. Pharmacologic inhibitors were employed to further assess the role of the JAK2/STAT3 and MAPK/ERK pathways in the proliferative response.</span></p></div><div><h3>Result(s)</h3><p><span>The presence of OB-R was confirmed in clinical leiomyoma and myometrial tissue obtained from 3 separate human subjects using immunofluorescence staining, and the expression of OB-R in HuLM cells was identified using immunoblotting. There was no significant difference in the expression of the leptin receptor in the </span>myometrium<span> compared with that in the leiomyoma tissue. Leptin stimulated cell proliferation and extracellular matrix<span> (ECM) deposition at 24 hours after treatment. Pretreatment with a JAK2/STAT3 inhibitor attenuated ECM deposition, and pretreatment with a MAPK/ERK inhibitor significantly decreased leptin’s stimulatory effect on cell proliferation and ECM deposition.</span></span></p></div><div><h3>Conclusion(s)</h3><p>Leptin induces a proliferative response and ECM deposition in HuLM cells. These findings suggest that leptin, acting through the JAK2/STAT3 and MAPK/ERK pathways, is involved in the development of uterine leiomyomas, which may partly explain their increased incidence in obese women.</p></div>","PeriodicalId":73012,"journal":{"name":"F&S science","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"F&S science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666335X22000398","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Objective

To investigate the molecular effects of leptin on uterine leiomyoma cells.

Design

Experimental study using in vitro culture of immortalized human leiomyoma (HuLM) cells.

Setting

Academic university center.

Patient(s)

Women with uterine fibroids who underwent a hysterectomy or myomectomy.

Intervention(s)

Administration of human recombinant leptin to the media of cultured HuLM cells separately or in combination with pharmacologic Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) or mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) inhibitors.

Main Outcome Measure(s)

We examined HuLM tissues and cells for the expression of the leptin receptor, termed OB-R. Cellular proliferation was measured at 6, 24, and 48 hours using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay. Protein expression levels of proliferating cell nuclear antigen, collagen 1, phosphorylated STAT3/total STAT3, and phosphorylated ERK1/2 and total ERK1/2 were quantified using immunoblotting. Pharmacologic inhibitors were employed to further assess the role of the JAK2/STAT3 and MAPK/ERK pathways in the proliferative response.

Result(s)

The presence of OB-R was confirmed in clinical leiomyoma and myometrial tissue obtained from 3 separate human subjects using immunofluorescence staining, and the expression of OB-R in HuLM cells was identified using immunoblotting. There was no significant difference in the expression of the leptin receptor in the myometrium compared with that in the leiomyoma tissue. Leptin stimulated cell proliferation and extracellular matrix (ECM) deposition at 24 hours after treatment. Pretreatment with a JAK2/STAT3 inhibitor attenuated ECM deposition, and pretreatment with a MAPK/ERK inhibitor significantly decreased leptin’s stimulatory effect on cell proliferation and ECM deposition.

Conclusion(s)

Leptin induces a proliferative response and ECM deposition in HuLM cells. These findings suggest that leptin, acting through the JAK2/STAT3 and MAPK/ERK pathways, is involved in the development of uterine leiomyomas, which may partly explain their increased incidence in obese women.

瘦素通过JAK2/STAT3和MAPK/ERK通路诱导平滑肌瘤细胞增殖和细胞外基质沉积
目的探讨瘦素对子宫平滑肌瘤细胞的分子作用。目的:体外培养永生化人平滑肌瘤(HuLM)细胞。背景:学术大学中心:接受子宫切除术或子宫肌瘤切除术的子宫肌瘤患者。干预措施:将人重组瘦素单独或联合药物Janus kinase 2 (JAK2)/信号传导和转录激活因子3 (STAT3)或丝裂原活化蛋白激酶(MAPK)/细胞外信号调节激酶(ERK)抑制剂给予培养的HuLM细胞培养基。我们检查了HuLM组织和细胞中瘦素受体(OB-R)的表达。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基- 2h -溴化四氮唑测定6、24和48小时的细胞增殖。采用免疫印迹法定量测定增殖细胞核抗原、胶原蛋白1、磷酸化STAT3/总STAT3、磷酸化ERK1/2和总ERK1/2蛋白表达水平。使用药物抑制剂进一步评估JAK2/STAT3和MAPK/ERK通路在增殖反应中的作用。结果(5)通过免疫荧光染色证实了OB-R在3个独立的人的临床平滑肌瘤和子宫肌瘤组织中的存在,并通过免疫印迹法鉴定了OB-R在HuLM细胞中的表达。肌层中瘦素受体的表达与平滑肌瘤组织中瘦素受体的表达无显著差异。瘦素在治疗后24小时刺激细胞增殖和细胞外基质(ECM)沉积。JAK2/STAT3抑制剂预处理可减弱ECM沉积,MAPK/ERK抑制剂预处理可显著降低瘦素对细胞增殖和ECM沉积的刺激作用。结论(5)瘦素可诱导HuLM细胞的增殖反应和ECM沉积。这些发现表明,瘦素通过JAK2/STAT3和MAPK/ERK通路参与了子宫平滑肌瘤的发展,这可能部分解释了肥胖女性子宫平滑肌瘤发病率增加的原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
F&S science
F&S science Endocrinology, Diabetes and Metabolism, Obstetrics, Gynecology and Women's Health, Urology
CiteScore
2.00
自引率
0.00%
发文量
0
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信